Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-04-01
2008-03-18
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S410000, C540S058000, C548S426000
Reexamination Certificate
active
07345034
ABSTRACT:
Azacyclosteroid histamine-3 receptor ligands, pharmaceutical compositions comprising such compounds, and methods for using such compounds and compositions are described herein.
REFERENCES:
patent: 3063987 (1962-11-01), Pappo
patent: 3152120 (1964-10-01), Vlasios et al.
patent: 3485825 (1969-12-01), Marx et al.
patent: 6143749 (2000-11-01), Bhagwat et al.
patent: 1 170945 (1969-11-01), None
patent: 1 230 681 (1971-05-01), None
Salimuzzaman Siddiqui, Proceedings of the Pakistan Acad. of Sciences, 18(2): 89-108, 1981, English Abstract Only.
Bjenning et al., “Peripherally Administered Ciproxifan Elevates Hypothalamic Histamine Levels And Potently Reduces Food Intake in the Sprague Dawley Rat,” Histamine Research In The New Mellennium, Proceedings Of The International Sendai Histamine Symposium Held In Sendai, Japan, Nov. 22-25, 2000, p. 449-450.
De Almeida et al., “Memory Facilitation by Histamine,” Arch. Int. Pharmacodyn., 283:193-198 (1986).
Delaunois et al., “Modulation Of Acetylcholine, Capsaicin and Substance P Effects by Histamine H3Receptors in Isolated Perfused Rabbit Lungs,” European Journal Of Pharmacology, 277:243-250 (1995).
Dimitriadou et al., “Functional Relationship Between Mast Cells and C-Sensitive Nerve Fibres Evidenced by Histamine H3-Receptor Modulation in Rat Lung and Spleen,” Clinical Science, 87:151-163 (1994).
Duméry et al., “Development of Amygdaloid Cholinergic Mediation of Passive Avoidance Learning in the Rat,”Exp. Brain. Res., 67:61-69 (1987).
Fitzsimons et al., “Histamine Receptors Signalling in Epidermal Tumor Cell Lines With H-rasGene Alterations,” Inflamm. Res., 47, Supplement 1, S50-S51 (1998).
Fox et al., “Effects of Histamine H3Receptor Ligands GT-2331 And Ciproxifan in a Repeated Acquisition Response in the Spontaneously Hypertensive Rat Pup,” Behavioural Brain Research 131:151-161 (2002).
Haas et al., Subcortical Modulation of Synaptic Plasticity in the Hippocampus, Behavioural Brain Research, 66:41-44 (1995).
Hatta et al., “Activation of Histamine H3Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Ischemia1,2,” The Journal Of Pharmacology And Experimental Therapeutics, 283(2):494-500 (1997).
Imamura et al., “Activation Of Histamine H3-Receptors Inhibits Carrier-Mediated Norepinephrine Release During Protracted Myocardial Ischemia,” Circulation Research, 78(3):475-481 (1996).
Imamura et al., “Histamine H3-Receptor-Mediated Inhibition Of Calcitonin Gene-Related Peptide Release From Cardiac C Fibers,” Circulation Research, 78(5):863-869 (1996).
Itoh et al., “Thioperamide, A Histamine H3Receptor Antagonist, Powerfully Suppresses Peptide YY-Induced Food Intake In Rats,” Biol. Psychiatry 45:475-481 (1999).
Kamei et al., “Influence Of Certain H1-Blockers On The Step-Through Active Avoidance Response In Rats,”Psychopharmacology, 102:312-318 (1990).
Kamei et al., “Participation Of Histamine In The Step-Through Active Avoidance Response And Its Inhibition By H1-Blockers,” Japan J. Pharmacol., 57:473-482 (1991).
Leurs et al., “The Histamine H3-Receptor: A Target For Developing New Drugs,” Progress In Drug Research, 39:127-165 (1992).
Leurs et al., “The Medicinal Chemistry And Therapeutic Potentials Of Ligands Of The Histamine H3Receptor,” Progress In Drug Research, 45:107-165 (1995).
Leurs et al., “Therapeutic Potential Of Histamine H3Receptor Agonists And Antagonists,” Trends In Pharm. Sci, 19:177-183 (1998).
Levi et al., “Histamine H3-Receptors: A New Frontier In Myocardial Ischemia,” The Journal Of Pharmacology And Experimental Therapeutics, 292(3):825-830 (2000).
Lin et al., “Involvement Of Histaminergic Neurons In Arousal Mechanisms Demonstrated With H3-Receptor Ligands In The Cat,” Brain Research, 523:325-330 (1990).
Matsubara et al., “UK-14,304, R(—) ∀-Methyl-Histamine And SMS 201-995 Block Plasma Protein Leakage Within Dura Mater By Prejunctional Mechanisms,” European Journal Of Pharmacology, 224:145-150 (1992).
Mazurkiewicz-Kwilecki et al., “Changes In The Regional Brain Histamine And Histidine Levels In Postmortem Brains Of Alzheimer Patients,” Can. J. Physiol. Pharmacol, 67: 75-78 (1989).
McLeod et al., “Histamine H3Antagonists,” Progress In Resp. Research 31:133-134 (2001).
Monti et al., “Effects Of Selective Activation Or Blockade Of The Histamine H3Receptor On Sleep And Wakefulness,” European Journal Of Pharmacology, 205:283-287 (1991).
Monti et al., “Sleep And Waking During Acute Histamine H3Agonist BP2.94 Or H3Antagonist Carboperamide (MR 16155) Administration In Rats,” Neuropsychopharmacology, 15(1):31-35 (1996).
Murakami et al., “AQ-0145, A Newly Developed Histamine H3Antagonist, Decreased Seizure Susceptibility Of Electrically Induced Convulsions In Mice,” Meth. Find. Exp. Clin. Pharmacol. 17(C):70-73 (1995).
Onodera et al., “Neuropharmacology Of The Histaminergic Neuron System In The Brain And Its Relationship With Behavioral Disorders,” Progress In Neurobiology, 42:685-702 (1994).
Perez-Garcia et al., “Effects Of Histamine H3Receptor Ligands In Experimental Models Of Anxiety And Depression,” Psychopharmacology 142:215-220 (1999).
Phillips et al., “Recent Advances In Histamine H3Receptor Agents,” Annual Reports In Medicinal Chemistry, 33:31-40 (1998).
Rouleau, “Bioavailability, Antinociceptive And Antiiflammatory Properties Of BP 2-94, A Histamine H3Receptor Agonist Prodrug,” The Journal Of Pharmacology And Experimental Therapeutics, 281(3):1085-1094 (1997).
Sakai et al., “Effects Of Thioperamide, A Histamine H3Receptor Antagonist, On Locomotor Activity And Brain Histamine Content In Mast Cell-DeficientW/WVMice,” Life Sciences, 48:2397-2404 (1991).
Schwartz et al., “Histaminergic Transmission in the Mammalian Brain,” Physiological Reviews 71(1):1-51 (1991).
Schwartz et al., “Histamine,” Psychopharmacology: The Fourth Generation Of Progress, 397-405 (1995).
Shaywitz et al., “Dopaminergic But Not Noradrenergic Mediation Of Hyperactivity And Performance Deficits In The Developing Rat Pup,” Psychopharmacology, 82:73-77 (1984).
Szelag, “Role Of Histamine H3-Receptors In The Proliferation Of Neoplastic Cells In Vitro,” Med. Sci. Monit., 4(5):747-755 (1998).
Tedford et al., “Cognition And Locomotor Activity In The Developing Rat: Comparisons Of Histamine H3Receptor Antagonists And ADHD Therapeutics,” Society For Neuroscience Abstr., 22:22 (1996).
Tedford et al., “Pharmacological Characterization Of GT-2016, A Non-Thiourea-Containing Histamine H3Receptor Antagonist: In Vitro And In Vivo Studies,” The Journal Of Pharmacology And Experimental Therapeutics, 275(2):598-604 (1995).
Tedford, “Clinical Applications Of HA H3Receptor Antagonists In Learning And Memory Disorders,” The Histamine H3Receptor 269-286 (1998).
Van de Woude et al, “Amino steroids-Conanine and heteroconanine derivatives” Bulletin des Societes Chimiques Belges, 82: 49-62 (1973).
Wada et al., Is The Histaminergic Neuron System A Regulatory Center For Whole-Brain Activity?, Trends In Neurosciences, 14(9):415-418 (1991).
Yates et al., “Effects Of A Novel Histamine H3Receptor Antagonist, GT-2394, On Food Intake And Weight Gain In Sprague-Dawley Rats,” Abstracts, Society For Neuroscience, 102.10:219 (Nov. 2000).
Yokoyama et al., “Effect Of Thioperamide, A Histamine H3Receptor Antagonist, On Electrically Induced Convulsions In Mice,” Journal Of Pharmacology, 234:129-133 (1993).
Yokoyama et al., “Histamine And Seizures Implications For The Treatment Of Epilepsy,” CNS Drugs, 5(5):321-330 (1996).
Salimuzzaman et al, “Some extension of von Braun BrCN reaction
Bennani Youssef L.
Cowart Marlon D.
Sun Minghua
Zhao Chen
Abbott Laboratories
Badio Barbara P.
Chen Portia
LandOfFree
Azacyclosteroid histamine-3 receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azacyclosteroid histamine-3 receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azacyclosteroid histamine-3 receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3976693